![](/img/cover-not-exists.png)
Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm (MPN)-Associated Intermediate- or High-Risk Myelofibrosis (MF) Resistant or Intolerant to Ruxolitinib: An Updated Analysis of the Phase II JAKARTA2 Study
Harrison, Claire, Schaap, Nicolaas, Vannucchi, Alessandro, Kiladjian, Jean-Jacques, Jourdan, Eric, Silver, Richard, Schouten, Harry, Passamonti, Francesco, Zweegman, Sonja, Talpaz, Moshe, Verstovsek,Volume:
19
Language:
english
Journal:
Clinical Lymphoma Myeloma and Leukemia
DOI:
10.1016/j.clml.2019.07.375
Date:
September, 2019
File:
PDF, 72 KB
english, 2019